Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival.
The responses of 23 patients with agnogenic myeloid metaplasia (AMM) to androgen therapy were studied. Various clinical and laboratory parameters were analyzed for their value in determining response to therapy and length of survival. Fifty-seven percent of patients responded, as determined by a sustained increase in hematocrit within three months of therapy which thus eliminated the need for transfusions. Chromosome study of the abnormal hemic population was the best predictor of response: 92% of patients with normal chromosomes responded, while 78% of patients with chromosomal abnormalities did not. Responders had a mean survival time of five and a half years from the time of diagnosis as compared with two years for the nonresponders. The degree of thrombocytopenia, suppression of the ferrokinetic, and lack of activity in axial skeleton on bone marrow scans indicated severely compromised hemopoiesis in the nonresponders. The results suggest that in some patients with AMM, more extensive cytogenetic alterations in the abnormal hematopoietic cells result in an inability to respond to androgen therapy and that the chromosome study is the test most accurate for predicting the outcome of therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000728:Androgens / Q000627:therapeutic use*; D001853:Bone Marrow / Q000648:ultrastructure; D002869:Chromosome Aberrations; D002871:Chromosome Banding; D002875:Chromosomes / Q000187:drug effects*; D004912:Erythrocytes / Q000648:ultrastructure; D005260:Female; D006400:Hematocrit; D006801:Humans; D007501:Iron / Q000097:blood; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis
D000728:Androgens; D007501:Iron